Business
Half-year Report
Half-year Report.
About this update from Probiotix Health Plc
[{"type":"text","content":"\n\n30 August 2024\n \nProBiotix Health plc\n(\"ProBiotix\" or the \"Company\" or, together with its subsidiary, the \"Group\")\n \nUnaudited Interim Results to 30 June 2024\n \nProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2024.\n \nHighlights (including post period end)\n \n· Turnover: +84% to £1.01m (2023: £0.55m)\n· Gross Profit margin: +8% to 56% (2023: 48%)\n· Net loss reduced by 49% to £0.262m (2023: £0.512m)\n· Substantial progress expanding the sales pipeline in North America and Europe\n· Strategic partnership with a North American based contract manufacturer in late stage negotiations for bulk strains and finished formats\n· Key appointments in Head of Marketing and regional Sales Manager Europe\n· Operational separation from OptiBiotix Health due to conclude by the end of 2024\n· Signed agreement with Chinese consumer brand, DanCare, for InstaMelt - launch due in Q4 2024\n· Current trading shows continued good momentum.\n \nSteen Andersen, CEO of ProBiotix, commented: \"We are pleased with the performance of the Company for the first six months of the year, and the increasing market opportunity allows the Board to remain confident f...